Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Down 7.8% in December

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 1,377,300 shares, a drop of 7.8% from the December 15th total of 1,494,600 shares. Based on an average trading volume of 100 shares, the short-interest ratio is currently 13,773.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

Swedish Orphan Biovitrum AB (publ) stock opened at $28.30 on Friday. The firm has a fifty day simple moving average of $28.47 and a two-hundred day simple moving average of $28.40. Swedish Orphan Biovitrum AB has a twelve month low of $22.87 and a twelve month high of $32.25. The company has a market capitalization of $10.07 billion, a PE ratio of 47.97 and a beta of 0.51. The company has a quick ratio of 0.49, a current ratio of 0.73 and a debt-to-equity ratio of 0.30.

Analyst Upgrades and Downgrades

Separately, Barclays upgraded shares of Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.